๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Esophageal Squamous Cell Carcinoma (ESCC)
Clinical trial register · China

Esophageal Squamous Cell Carcinoma (ESCC) Trials in China, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Beijing 7 Guangzhou 5 Shanghai 5 Chongqing 2 Chengdu 2
Narrow the registerReset
Recruitment status
Phase
Site location
Beijing7 Guangzhou5 Shanghai5 Chongqing2 Chengdu2
All 16 locations
Target enrolment
to

Esophageal Squamous Cell Carcinoma (ESCC) trials in China

34 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Not yet open
Risk of Esophageal Cancer Returning After Immunotherapy, Chemotherapy, and Surgery
NCT07822906Esophageal Squamous Cell Carcinoma (ESCC)
Peking University Cancer Hospital & Institute
Observational
100
Beijing
2026-10-01
Not yet open
Sacituzumab Tirumotecan (Sac-TMT/SKB264) Plus Tagitanlimab (KL-A167) in Patients With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma and Gastric/Gastroesophageal Junction Adenocarcinoma
NCT07701681ESCC, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Esophageal Squamous Cell Carcinoma (ESCC)
Sun Yat-sen University
Phase 2
75
Guangzhou
2026-08-31
Recruiting
Neoadjuvant Chemoradiotherapy Combined With CTLA-4 Monoclonal Antibody Plus PD-1 Monoclonal Antibody for Locally Advanced Esophageal Cancer
NCT07751055Esophageal Squamous Cell Carcinoma (ESCC)
Sun Yat-sen University
Phase 2
51
Guangzhou
2026-08-01
Active, closed
Clinical Application of an AI-based Dissection Trajectory Prediction System (ADTPS) in Endoscopic Submucosal Dissection
NCT07757906Esophageal Squamous Cell Carcinoma (ESCC), High-Grade Intraepithelial Neoplasia, AI-Based Dissection Trajectory Prediction System
Qilu Hospital of Shandong University
Not applicable
160
Jinan
2026-07-29
Recruiting
PD-1 Inhibitors Combined With Local Therapy at Different Timings in Oligometastatic ESCC
NCT07697859Esophageal Squamous Cell Carcinoma (ESCC)
Fudan University
Observational
354
Shanghai
2026-07-15
Not yet open
Early Response-guided Sequential Radiotherapy After Chemoimmunotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma
NCT07721103Esophageal Squamous Cell Carcinoma (ESCC)
Tianjin Medical University Cancer Institute and Hospital
Phase 2
110
Tianjin
2026-07-14
Not yet open
Neoadjuvant Short-Course Radiotherapy Plus Tislelizumab and Chemotherapy for Locally Advanced Resectable Esophageal Squamous Cell Carcinoma
NCT07678580Esophageal Squamous Cell Carcinoma (ESCC)
Tang-Du Hospital
Phase 2
50
Xi'an
2026-07-10
Active, closed
Phase II Study of Induction Chemoimmunotherapy Followed by Radiotherapy and Organ Preservation in Resectable ESCC
NCT07711470Esophageal Squamous Cell Carcinoma (ESCC)
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2
140
Beijing
2026-07-01
Recruiting
Adebrelimab Combined With Neoadjuvant Chemotherapy in Borderline Resectable Locally Advanced Esophageal Squamous Cell Carcinoma
NCT07638436Esophageal Squamous Cell Carcinoma (ESCC)
Sun Yat-sen University
Phase 2
42
Guangzhou
2026-06-17
Active, closed
Low-Dose Radiotherapy With Retlirafusp Alfa and Chemotherapy as Neoadjuvant Therapy for Resectable Locally Advanced Esophageal Squamous Cell Carcinoma
NCT07682376Esophageal Squamous Cell Carcinoma (ESCC)
Harbin Medical University
Phase 2
96
Harbin
2026-06-10
Recruiting
Adebrelimab Combined With Neoadjuvant Chemoradiotherapy for Esophageal Squamous Cell Carcinoma
NCT07595770Esophageal Squamous Cell Carcinoma (ESCC)
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 2
37
Guangzhou
2026-05-22
Recruiting
QLC5508 vs. Chemotherapy in Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma
NCT07463573Esophageal Squamous Cell Carcinoma (ESCC)
Qilu Pharmaceutical Co., Ltd.
Phase 3
466
Beijing
2026-04-20
Not yet open
Short-course Radiotherapy Combined With Serplulimab and Chemotherapy as Neoadjuvant Treatment for Resectable ESCC
NCT07403435Esophageal Squamous Cell Carcinoma (ESCC)
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 2
22
Wuhan
2026-02-15
Not yet open
Indocyanine Green-guided Omental Shield Anastomosis for Cervical Esophagogastric Anastomosis in Minimally Invasive McKeown Esophagectomy
NCT07376876Esophageal Squamous Cell Carcinoma (ESCC), Esophageal Cancer
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Phase 2
73
Chongqing
2026-01-01
Recruiting
Induction Chemo-Immunotherapy + Radiotherapy vs Concurrent Chemoradiotherapy for Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma
NCT07559045Esophageal Squamous Cell Carcinoma (ESCC)
Second Affiliated Hospital of Zunyi Medical University
Phase 2
92
Zunyi
2026-01-01
Recruiting
KC1036 in Combination With PD-1 Antibody and Platinum-based Chemotherapy for First-line Advanced Esophageal Cancer
NCT07481058Esophageal Squamous Cell Carcinoma (ESCC)
Beijing Konruns Pharmaceutical Co., Ltd.
Phase 2
60
Beijing
2025-12-12
Recruiting
Intestinal Low-Dose Radiotherapy Plus Immunochemotherapy for Conversion of Borderline Resectable/Unresectable Esophageal Squamous Cell Carcinoma
NCT07339488Borderline Resectable Carcinoma, Unresectable Cancer, Esophageal Squamous Cell Carcinoma (ESCC), Immune Checkpoint Inhibitor
Chuangzhen Chen
Phase 2
43
Shantou
2025-12-05
By invitation
Infiltration Pattern of Locally Advanced ESCC
NCT07567716Esophageal Squamous Cell Carcinoma (ESCC), Infiltration, Tumour
Shanghai Chest Hospital
Observational
30
Shanghai
2025-10-01
Recruiting
The Efficacy and Safety of Iparomlimab and Tuvonralimab Injection Combined With Chemotherapy as the First-line Treatment for Esophageal Squamous Cell Carcinoma
NCT07290010Esophageal Squamous Cell Carcinoma (ESCC)
Hebei Medical University Fourth Hospital
Phase 2
25
Shijiazhuang
2025-09-26
Recruiting
Study of Tislelizumab Combined With Chemoradiotherapy and Surgery for Unresectable Esophageal Squamous Cell Carcinoma
NCT07039162Esophageal Squamous Cell Carcinoma (ESCC), Locally Advanced Unresectable Esophageal Cancer
Ming-Yu Lien
Phase 2
45
2025-09-26
Active, closed
Predictive Biomarkers for PD-1 Inhibitor Response in Squamous Cell Carcinoma
NCT07147361Esophageal Squamous Cell Carcinoma (ESCC), Cervical Squamous Cell Carcinoma, Lung Squamous Cell Carcinoma, Head and Neck Squamous Carcinoma
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Observational
800
Beijing
2025-09-12
Active, closed
A Study of Trifluridine/Tipiracil Combined With Anlotinib as Second-line Treatment for Recurrent and Metastatic Esophageal Squamous Cell Carcinoma
NCT07142421Esophageal Squamous Cell Carcinoma (ESCC)
First Affiliated Hospital of Zhejiang University
Phase 2
35
Hangzhou
2025-08-06
Recruiting
Neoadjuvant Immunotherapy Combined With Chemotherapy Sequenced With Endoscopic Resection for Esophageal Cancer (Endosurgery-02)
NCT07317609Esophageal Squamous Cell Carcinoma (ESCC)
Shanghai Zhongshan Hospital
Phase 1
60
Shanghai
2025-07-15
Recruiting
Hypofractionated vs. Conventional Chemoradiotherapy After Induction Chemo-immunotherapy for Unresectable Esophageal Squamous Cell Carcinoma
NCT06912074Esophageal Squamous Cell Carcinoma (ESCC)
Sun Yat-sen University
Phase 2
134
Guangzhou
2025-04-05
Not yet open
Total Neoadjuvant Therapy Combined With Adebrelimab in Locally Advanced Resectable ESCC
NCT06861777Esophageal Squamous Cell Carcinoma (ESCC)
YIN LI
Phase 2/3
474
Beijing
2025-03
Active, closed
NCRT Combined With Sequential Perioperative PD-1 Inhibitor for LAESCC
NCT06762158Esophageal Squamous Cell Carcinoma (ESCC)
RenJi Hospital
Not applicable
50
Shanghai
2024-10-30
Recruiting
Tumor Regression Grade As Predictor of Adjuvant Therapy
NCT06710665Esophageal Squamous Cell Carcinoma (ESCC)
Fujian Medical University Union Hospital
Observational
400
Fuzhou
2024-10-01
Recruiting
Neoantigen Vaccines in Esophageal Squamous Cell Carcinoma
NCT06675201Esophageal Squamous Cell Carcinoma (ESCC), Neoantigen-loaded Dendritic Cell Vaccine, Immune Checkpoint Inhibitors (ICIs)
Sichuan University
Phase 2
165
Chengdu
2024-10-01
By invitation
A Multicenter Trial of YSQTG vs. Simulated Agents With Neoadjuvant Chemoradiotherapy or Chemoimmunotherapy for EC
NCT06863831Esophageal Squamous Cell Carcinoma (ESCC)
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Not applicable
536
Beijing
2024-08-22
By invitation
Immunochemotherapy ยฑ Salvage Chemoradiation for Local Recurrence of Esophageal Squamous Cell Carcinoma After Definitive Chemoradiotherapy
NCT07016737Esophageal Squamous Cell Carcinoma (ESCC)
Ye jinjun
Phase 3
79
Nanjing
2024-08-01
Recruiting
Low-Dose Involved-Field Radiotherapy Plus Immunochemotherapy for ESCC
NCT06603402Esophageal Squamous Cell Carcinoma (ESCC), Immunotherapy
Sichuan University
Phase 2
41
Chengdu
2023-08-24
Recruiting
An Observational Study on the Safety and Efficacy of Immunotherapy Combined With Concurrent Chemoradiotherapy in Elderly Patients With Esophageal Squamous Cell Carcinoma
NCT07080437Esophageal Squamous Cell Carcinoma (ESCC)
Three Gorges Hospital of Chongqing University
Observational
40
Chongqing
2021-03-01
Rows per page Showing 1–34 of 34
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 26 September 2026. https://priyalifescience.com/clinical-trials-china/condition/esophageal-squamous-cell-carcinoma-escc

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 34 of those studies listing the condition Esophageal Squamous Cell Carcinoma (ESCC).

How many Esophageal Squamous Cell Carcinoma (ESCC) trials are recruiting in China?

17 of the 34 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 8 have not yet opened recruitment, 6 are active but closed to new participants, and 3 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Esophageal Squamous Cell Carcinoma (ESCC)), 34 studies
PhaseStudiesRecruitingShare
Phase 2201258.8%
Observational6317.6%
Not applicable308.8%
Phase 3318.8%
Phase 1112.9%
Phase 2/3102.9%

Most active sponsors

Lead sponsors with the most studies (Esophageal Squamous Cell Carcinoma (ESCC))
Lead sponsorStudiesRecruiting
Sun Yat-sen University43
Cancer Institute and Hospital, Chinese Academy of Medical Sciences30
Shanghai Chest Hospital21
Sichuan University22
Tang-Du Hospital20
Beijing Konruns Pharmaceutical Co., Ltd.11
Chuangzhen Chen11
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University10
First Affiliated Hospital of Zhejiang University10
Fudan University11
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.